Artificial Intelligence (AI) aids in effective data collection and management and, thus, acts as a game changer for life science companies involved in the drug development process. The adoption of AI drives innovative ways of collecting clinical trial data and reducing dependency on manual operations. This can be well illustrated by the following used case: AstraZeneca has collected oncology data, including clinical and imaging data, of more than 100,000 consenting patients for different clinical studies. To transform the process of oncology data feed, the team adopts complex datasets for accessibility, interoperability, and reusability of data through "FAIR." Such integration allows the collected data from specific clinical trials and projects to be accessible across the company's drug development teams, in compliance with data protection laws. Further, AstraZeneca is working with external companies such as Tempus to leverage real-world data and represent patients across the region. Such strategic partnerships/inorganic strategies offer crucial evidence about patient outcomes in a healthcare system without revealing the identity of the clinical trial participants in the datasets. Thus, the increasing application of AI for processing clinical trial data is likely to catalyze the growth of the Asia Pacific clinical trial imaging market in the coming years.
The Asia Pacific clinical trial imaging market is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. China held the largest share in the market in 2022, and it is expected to register the highest CAGR of 8.6% during the forecast period. The growth is due to the established pharmaceutical, a rise in R&D expenditure by the pharmaceutical and biopharmaceutical companies, a surge in clinical trials due to lower cost, well-established healthcare technologies, the launch of innovative products by key players, and favorable regulatory policies. China has the world’s second-largest pharmaceutical market. The excessive population in China, coupled with the rise of various communicable and noncommunicable diseases, is majorly driving the growth of pharmaceutical companies in China.
Asia Pacific Clinical Trial Imaging Market Segmentation
The Asia Pacific clinical trial imaging market is segmented on the basis of modality, offering, end user, and country.
Based on modality, the Asia Pacific clinical trial imaging market is segmented into tomography, magnetic resonance imaging (MRI), ultrasound, positron emission tomography (PET), X-ray, echocardiography, and others. The tomography segment registered the largest market share in 2023.
Based on offering, the Asia Pacific clinical trial imaging market is segmented into operational imaging services, imaging software, read analysis services, trial design and consulting services, and others. The operational imaging services segment held the largest market share in 2023.
Based on end user, the Asia Pacific clinical trial imaging market is segmented into contract research organizations (CROs), pharmaceutical and biotechnology companies, academic and research institutes, and others. The contract research organizations (CROs) segment held the largest market share in 2023.
Based on country, the market is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. China dominated the market share in 2023.
Calyx Inc, eResearch Technology Inc, ICON PLC, IXICO plc, Medical Metrics Inc, Radiant Sage LLC, VIDA Diagnostics Inc, and WCG Clinical Inc are the leading companies operating in the Asia Pacific clinical trial imaging market.
| Report Attribute | Details |
|---|---|
| Market size in 2023 | US$ 373.46 Million |
| Market Size by 2028 | US$ 553.11 Million |
| CAGR (2023 - 2028) | 8.2% |
| Historical Data | 2021-2022 |
| Forecast period | 2024-2028 |
| Segments Covered |
By Modality
|
| Regions and Countries Covered |
Asia-Pacific
|
| Market leaders and key company profiles |
|
The Asia Pacific Clinical Trial Imaging Market is valued at US$ 373.46 Million in 2023, it is projected to reach US$ 553.11 Million by 2028.
As per our report Asia Pacific Clinical Trial Imaging Market, the market size is valued at US$ 373.46 Million in 2023, projecting it to reach US$ 553.11 Million by 2028. This translates to a CAGR of approximately 8.2% during the forecast period.
The Asia Pacific Clinical Trial Imaging Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Asia Pacific Clinical Trial Imaging Market report:
The Asia Pacific Clinical Trial Imaging Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Asia Pacific Clinical Trial Imaging Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Asia Pacific Clinical Trial Imaging Market value chain can benefit from the information contained in a comprehensive market report.
Please tell us your area of interest
(Market Segments/ Regions and Countries/ Companies)
E 1803, Panchshil Towers,
Wagholi, Haveli,
Pune - 412207,
Maharashtra, India
US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For Asia Pacific Clinical Trial Imaging Market
